Becton, Dickinson and Company (BDX) Stock Forecast & Price Target

$247.63 -0.86 (-0.35%)

Closing price 03:59 PM Eastern

Extended Trading

$247.60 -0.03 (-0.01%)

As of 06:24 PM Eastern

Becton, Dickinson and Company - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 7 Analyst Ratings

Sell
0

Hold
0

Buy
7

Based on 7 Wall Street analysts who have issued ratings for Becton, Dickinson and Company in the last 12 months, the stock has a consensus rating of "Buy." Out of the 7 analysts, 7 have given a buy rating for BDX.

Consensus Price Target

$283.00
14.28% Upside

According to the 7 analysts' twelve-month price targets for Becton, Dickinson and Company, the average price target is $283.00. The highest price target for BDX is $312.00, while the lowest price target for BDX is $270.00. The average price target represents a forecasted upside of 14.28% from the current price of $247.63.

Get the Latest News and Ratings for BDX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Becton, Dickinson and Company and its competitors.

BDX Analyst Ratings Over Time

Type	Current Forecast 2/1/24 to 1/31/25	1 Month Ago 1/2/24 to 1/1/25	3 Months Ago 11/3/23 to 11/2/24	1 Year Ago 2/1/23 to 2/1/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	6 Buy rating(s)	8 Buy rating(s)	5 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	1 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$283.00	$283.50	$282.63	$278.83
Forecasted Upside	14.28% Upside	24.96% Upside	20.14% Upside	15.07% Upside
Consensus Rating	Buy	Buy	Buy	Moderate Buy

BDX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BDX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Becton, Dickinson and Company Stock vs. The Competition

Type	Becton, Dickinson and Company	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.81	2.53
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	13.89% Upside	14,141.56% Upside	11.35% Upside
News Sentiment Rating	Positive News See Recent BDX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
1/28/2025	Piper Sandler 2 of 5 stars	Jason Bednar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Overweight ➝ Overweight	$275.00 ➝ $280.00	+12.65%
10/1/2024	Evercore ISI 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$286.00 ➝ $290.00	+20.29%
10/1/2024	Citigroup 3 of 5 stars	J. Wuensch Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$255.00 ➝ $275.00	+14.08%
8/2/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$275.00 ➝ $270.00	+12.55%
7/26/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$270.00 ➝ $280.00	+17.80%
5/30/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$274.00	+21.82%
5/6/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight ➝ Overweight	$305.00 ➝ $312.00	+31.85%
12/4/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$310.00 ➝ $280.00	+17.52%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 06:51 PM ET.

Should I Buy Becton, Dickinson and Company Stock? BDX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, January 23, 2025. Please send any questions or comments about these Becton, Dickinson and Company pros and cons to contact@marketbeat.com.

Becton, Dickinson and Company
Bull Case

Here are some ways that investors could benefit from investing in Becton, Dickinson and Company:

Becton, Dickinson and Company has a strong institutional ownership, with 86.97% of its stock held by institutional investors, indicating confidence in the company's stability and growth potential.
The stock recently traded at $237.57, showing a 0.5% increase, which may suggest positive market sentiment and potential for further appreciation.
Analysts have given Becton, Dickinson and Company an average rating of "Moderate Buy," with several upgrades in recent months, reflecting optimism about the company's future performance.
Recent acquisitions by institutional investors, such as Sax Wealth Advisors LLC acquiring 1,572 shares valued at approximately $357,000, highlight growing interest and confidence in the company's prospects.
The company has a diverse product portfolio in medical supplies and devices, which positions it well to benefit from ongoing demand in the healthcare sector.

Becton, Dickinson and Company
Bear Case

Investors should be bearish about investing in Becton, Dickinson and Company for these reasons:

Insider selling has been observed, with insiders selling 9,844 shares valued at $2,210,716, which may raise concerns about the company's internal confidence.
Recent downgrades from analysts, such as StockNews.com reducing the rating from "buy" to "hold," could indicate potential challenges ahead for the company's stock performance.
The stock's fifty-day moving average is $227.07, which is below the current trading price, suggesting potential volatility and uncertainty in the short term.
Despite recent growth, the company faces competition in the medical instruments sector, which could impact its market share and profitability.
Market conditions and economic factors can affect healthcare spending, which may pose risks to Becton, Dickinson and Company's revenue growth.

BDX Forecast - Frequently Asked Questions

: According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Becton, Dickinson and Company is $283.00, with a high forecast of $312.00 and a low forecast of $270.00.
: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Becton, Dickinson and Company in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BDX shares.
: According to analysts, Becton, Dickinson and Company's stock has a predicted upside of 14.28% based on their 12-month stock forecasts.
: Becton, Dickinson and Company has been rated by research analysts at Piper Sandler in the past 90 days.
: Analysts like Becton, Dickinson and Company more than other "medical" companies. The consensus rating for Becton, Dickinson and Company is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BDX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This page (NYSE:BDX) was last updated on 1/31/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Becton, Dickinson and Company (BDX) Stock Forecast & Price Target